Lilly Ventures acts as lead investor for Cerulean Pharma's $24m C round.
Cerulean Pharma, a lung cancer biotechnology company formerly known as Tempo Pharmaceuticals, has raised $24m in its series C round with Lilly Ventures as lead investor.
Lilly Ventures, the corporate venturing unit of drugs company Eli Lilly, was joined in the consortium by venture capital firms Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners, property group Alexandria Real Estate Equities, and angel investor William Rastetter, the former executive chairman of biotech peer Biogen Idec and part of Venrock.…
